the damage of ischemic myocardium can cause ischemic-reperfusion injury in heart by elevated expression of IL-17 and IL-17RA receptor subunits. [7] [8] [9] with TNF receptor-associated factor 2 (TRAF2) and TRAF5 and lead to increased stability of CXCL1 mRNA. Thus, the inflammatory and pro-atherogenic function of IL-17A can be aggravated. 10, 11 Act1-deficient mice models have revealed that Act1-dependent IL-17 signaling pathway is pivotal for pathogenesis of EAE, 12 collageninduced arthritis (CIA), and colitis. 13, 14 Previous reports reveal that the rs33980500 and rs13210247 SNPs in TRAF3IP2 gene are markedly associated with inflammatory diseases. 15, 16 According to the role of IL-17A signals in augmentation of inflammatory conditions and its link to the pathogenesis of MI, we hypothesized that polymorphisms in Act1, the key adaptor molecule in IL-17A signaling pathway, are correlated with myocardial infarction or its outcome in patients. Selection of polymorphisms was based on a thorough search on all validated SNPs within TRAF3IP2 gene in NCBI databases. Based on previous studies, the rs33980500 SNP affects downstream signaling by altering the expression of protein (Act1), and along with rs13210247 is associated with several inflammatory diseases. Therefore, we studied both SNPs in the TRAF3IP2 adaptor (Act1) gene in patients who were hospitalized because of myocardial infarction. The SNP frequencies were also defined in a group of healthy blood donors in the same geographic region. Since previous studies have shown that certain genotypes of rs33980500 from TRAF3IP2 reinforce the stability of CXCL1 mRNA, we also evaluated the relationship of CXCL1 plasma levels with TRAF3IP2 genotypes in patients.
| METHODS AND MATERIALS

| Study population
All confirmed MI cases (n = 201) referring to the affiliated hospitals of Shiraz University of Medical Sciences in a 1-year period were included in this study. MI diagnosis was approved by collaborating cardiologist on the basis of typical ECG changes and increased cardiac markers. The MI diagnosis was confirmed by coronary angiography. The patients' clinical and pathological criteria are shown in Table 1 . Control individuals (n = 201) were selected from among healthy blood donors of the same age range and gender (mean age ± SD = 57.80 ± 11.8 years, 175 Male/26 Female) who referred to Fars Blood Transfusion Center. First, they were examined by a physician and were evaluated for underlying diseases, including: cardiovascular diseases, hyperthyroidism, hypertension, pulmonary diseases, stroke, diabetes, cancer, and autoimmune diseases.
Second, they were asked and examined for recent infectious diseases including common cold, influenza, lung infection, urinary tract infection, brucellosis, tuberculosis, and typhoid and excluded if positive. Third, the recipients of recent surgery and dentistry and those who were on any medications such as antibiotics, aspirin, propranolol, or had recently received any vaccine or blood products were excluded from study. Travel to endemic malaria areas in the country, tattooing, acupuncture, high or low blood pressure and anemia, favism, and risky behaviors were also considered as exclusion criteria. Blood samples from these individuals were further tested for infectious diseases such as hepatitis C, hepatitis B, AIDS, and syphilis. All of these 201 peoples were negative for those criteria.
The lipid panel (HDL, LDL, TG, and cholesterol) and blood glucose levels were not studied due to the fact that the control individuals were not fasting. Having said so, we only included individuals who had their lipid profile and blood sugar levels checked up to 3 months before sampling and turned normal. 
| Genotyping
We studied two SNPs in TRAF3IP2 gene: one coding polymorphism rs33980500 and an intronic one called rs13210247. PCR and RFLP methods were established and used for genotyping of noted SNPs.
PCR procedure was performed in a 15 μL total reaction volume containing 200 μM of each dNTPs, 300 ng genomic DNA, 2 mM of MgCl 2 , 10X PCR Buffer, 1U Taq DNA polymerase, and 1.0 μM of each primer.
Then, the related restriction enzyme was added to PCR products and incubated at 37°C overnight in a dry block. The primers sequences, required restriction enzyme, recognition site of restriction enzyme, and length of cleaved products are shown in Table 2 . The enzymatically cleaved products were electrophoresed on a 3.5 agarose gel containing 2.5 μL safe stain and visualized by UV light at 254 nm ( Figures 1 and 2 ).
| Cytokine measurement
CXCL1 plasma levels in 126 MI patients and 50 normal subjects were measured by the Human CXCL1 (MGSA alpha, Thermo scientific, USA)
ELISA assay. Due to financial inadequacies, chemokine measurement was not performed in all patients and healthy individuals. Selected patients and healthy controls representing different genotypes were included in this assay.
| RESULTS
| Genotype distributions and allelic prevalence
The genotype distributions and allelic prevalence of studied SNPs are shown in Table 3 . Two studied SNPs in patient and control groups followed Hardy-Weinberg equilibrium. As indicated in Table 3, TRAF3IP2 (rs33980500) and TRAF3IP2 (rs13210247) SNPs showed no significant difference in allelic and genotype distributions between patients and controls (Table 3) . Moreover, logistic binary regression after correction for sex and age confirmed the results of chi-square showing that TRAF3IP2 rs13210247 and rs33980500 alleles (P = .35 and P = .31, respectively) and genotypes (P > .05 for all genotypes) do not increase the susceptibility to myocardial infarction. The analysis based on dominant, recessive, and additive models showed no increase in the F I G U R E 1 PCR-RFLP products corresponding to the TRAF3IP2 rs33980500 polymorphism F I G U R E 2 PCR-RFLP products corresponding to the TRAF3IP2 rs13210247 polymorphism susceptibility to myocardial infarction by the mutant genotypes (data not shown).
The analysis of TRAF3IP2 (rs33980500) and TRAF3IP2 (rs13210247) haplotypes was performed by LD2SNPing v2.0 and statistical EPI-INFO 7 softwares. There was no significant difference between healthy individuals and patients with MI in respect to TRAF3IP2 (rs33980500) and TRAF3IP2 (rs13210247) haplotypes (Table 4 , P = .05).
| Associations of TRAF3IP2 (rs33980500) and TRAF3IP2 (rs13210247) genes variants with clinicopathologic characteristics of patients
T allele and TT genotype in TRAF3IP2 (rs33980500) polymorphism were associated with female gender, diastolic dysfunction, mechanical complications of heart, left main artery stenosis, anterolateral hypokinesis, and left ventricular ejection fraction; however, CT genotype was associated with positive family history of the diseases. Binary regression analysis confirmed the association of T allele with gender (P = .043, OR = 2.24), family history of cardiovascular disease (P = .024, OR = 2.30), diastolic dysfunction (P = .01, OR = 3.76), mechanical complications of the heart (P = .01, OR = 2.7), and left main artery stenosis (P < .0001, OR = 31.033) ( Table 5) .
Also binary regression analysis confirmed the association of the G allele of TRAF3IP2 rs13210247 with the mechanical complications of the heart (P = .01, OR = 3.29), but in spite of the primary analysis, correlation with left main artery stenosis (P = .06, OR = 2.826) and diastolic dysfunction did not reach the significant level (P = .06, OR = 4.27) ( Table 6 ).
| Comparison of CXCL1 plasma levels between patients and controls
In this study, plasma levels of CXCL1 in 126 patients and 50 controls were measured. Due to the lack of normal distribution in data, approved by Kolmogorov-Smirnov and Shapiro-Wilk statistical tests, we used the nonparametric Mann-Whitney test for comparison between groups. Statistical analysis showed a significant difference in the plasma levels of CXCL1 chemokine between MI patients and healthy controls (P = .0006, Figure 3 ).
| Associations between TRAF3IP2 (rs33980500) and (rs13210247) variants and CXCL1 chemokine levels
We investigated the association between plasma levels of CXCL1 chemokine with studied polymorphisms in patients and controls. Due to the low number of patients in each cluster of genotypes and high variance in the plasma levels of CXCL1, we used Kruskal-Wallis test for data analysis. We found a significant correlation between plasma contents of CXCL1 and TT genotype of TRAF3IP2 (rs33980500) polymorphism in patients (P = .04, Figure 4A ).
We also studied the association between plasma levels of CXCL1 and TRAF3IP2 (rs13210247) polymorphism in the healthy controls and MI patients. There again we observed non-significantly higher plasma levels of CXCL1 chemokine and the two patients with GG genotype (P = .056, Figure 4B ). However, the low number of patients in this group decreased the power of this result.
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| DISCUSSION
In our study, the highest correlation was observed between the risk allele of TRAF3IP2 rs33980500 with left main coronary artery stenosis.
Few studies have investigated the inflammatory processes in left main coronary artery stenosis among which a recent one showed a positive correlation between serum Chemerin, as an inflammatory marker, and the degree of stenosis. 18 This mutant/risk allele is reported to be associated with increased inflammation. 19 Inflammation reduces nitric oxide, cyclic guanosine, and activity of protein kinase G which lead to increase in myocardial hypertrophy and increased resting due to hypo phosphorylation of the cytoskeletal protein, titin, that can lead to a decrease in cardiac output. 20 Moreover, high serum levels of CRP along with leukocyte count are reported to predict poor outcome in patients with unprotected left main coronary artery stenosis. 21, 22 We also found significantly increased mutant/risk alleles of TRAF3IP2 (rs33980500, rs13210247) in MI patients with diastolic dysfunction compared with other patients. Myocardial infarction leads to loss of contractility and impairment of heart ventricular dilation resulting in reduction of systolic and diastolic function.
Physiological phase diastolic function including active relaxation and passive filling are both affected by myocardial ischemia and myocardial infarction. Active relaxation after a heart attack is postponed, while changes in left ventricular stiffness depend on the rate of myocardial infarction and remodeling after myocardial infarction.
Interstitial edema and fibrosis increase the stiffness of the ventricle wall. MI patients with diastolic dysfunction have poorer prognosis compared with MI patient without diastolic dysfunction. [23] [24] [25] Therefore, the increased frequencies of TRAF3IP2 inflammatory variants in patients may be considered as a correlate of poor prog- The plasma levels of CXCL1 (pg/mL) compared between patients and controls based on the TRAF3IP2 rs13210247 genotype after a heart attack occur due to the lack of proper blood flow which leads to myocardial necrosis, neutrophil infiltration, activation of MMPs, and degradation of collagen by serine proteases which lead to slip myocytes, thin walls, increased wall stress, ventricular dilatation, and eventually ventricular septal rupture. The incidence of these three mechanical effects is very low, but is associated with very poor prognosis. 28 Previous studies have shown that western diet increases the expression of TRAF3IP2 in mice 29 and male transgenic mice with cardiomyocyte-specific TRAF3IP2 overexpression develop spontaneous myocardial hypertrophy, fibrosis, and dysfunction where a gender-dependent effect of TRAF3IP2 is suggested. 30 In addition, dipeptidyl peptidase-4 inhibition results in simultaneous reduction of TRAF3IP2, proinflammatory cytokine, and growth factor expression, as well as collagen induction in primary cardiac fibroblasts. 29 This phenomenon which reverses diastolic dysfunction through targeting TRAF3IP2 expression and its downstream inflammatory signaling has cardioprotective effects. 29 We observed an increase in the mutant/risk allele of TRAF3IP2 (rs33980500) in MI patients with anterolateral hypokinesia.
Hypokinesia is defined as less movement in parts of heart walls within each heartbeat. An inadequate blood supply leads to wall motion abnormalities, a condition such as myocardial infarction. Hypokinesia can reduce ejection fraction, cardiac output, and even cause organ failure. Patients with wall motion abnormality have lower cardiac output and higher CRP than individuals without the disorder. 31 In our study, there was a trend of increase in T allele and TT genotype in patients with lower EFs (Table 5 ). This observation is noteworthy because rs33980500 results in the substitution of an asparagine for an aspartic acid at position 10 of ACT1, which due to alternative splicing of its mRNA two ACT1 isoforms with different functionality are produced in fibroblasts but not in T cells. 32 Therefore, fibroblasts remain responsive to IL-17A and its signaling. Once again, these results underline the significance of TRAF3IP2 gene variants and its protein regulation in different diseases.
Our finding showed an increase in the mutant/risk allele of TRAF3IP2 (rs33980500) polymorphism in female patients. It is known that the clinical signs, treatment, diagnosis, and prognosis of cardiovascular disease in men and women are different. 33, 34 Previous studies have shown more deaths among women than men after MI. 35 Our results once again highlight the gender differences in genetics of myocardial infarction.
In this study, also we compared the plasma levels of CXCL1 chemokine between patients with MI and healthy subjects, and investigated the correlation between different genotypes of TRAF3IP2 polymorphisms and the plasma levels of CXCL1 in MI patients and healthy controls. CXCL1 is one of the target genes of IL-17A signaling pathway, levels of which may be affected by functional polymorphisms in TRAF3IP2 adaptor in this pathway. Elevated level of CXCL1 in patients with myocardial infarction is already reported. 7, 36, 37 However, the interesting finding was the significant correlation between TT genotype of TRAF3IP2 (rs33980500) and plasma levels of CXCL1 in MI patients. TT genotype reinforces the IL-17A signaling pathway in a direction, which leads to the stability of CXCL1 mRNA and by this mechanism may have led to increased levels of CXCL1 in the blood.
Our study had limitations in terms of cost and logistics for expanding sample size (which affected the power of study, especially for rs13210247 alleles) as well as testing lipid profile and blood sugar, blood pressure, and BMI of control individuals at the time of sampling.
| CONCLUSION
Our study showed no significant difference in the genotype distributions and allelic prevalence between cases and controls, however, we observed associations between mutant/risk alleles of studied polymorphisms of TRAF3IP2 and correlates of poor prognosis of MI.
TRAF3IP2 is the coding gene of Act1 adaptor molecule in the IL-17A signaling pathway which is increasingly known to be a main player in the pathogenic inflammation of various diseases. Our results reemphasize the role of inflammatory genetic factors in the coronary artery diseases and may provide information to identify molecules that can be targeted in therapeutic approaches. 
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